Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
Bladder cancer is not a rare disease. It is one of the 10 most common cancers in the UK and the 5th most common cancer in the European Union.
Read Full NewsIn patients with newly diagnosed fibromyalgia who have prominent symptoms of anxiety and depression, remission of depression — not pain reduction alone — determines clinical improvement.
Most ADHD coaches do not have behavioral health training, a study finds, but experts say peer support can help people navigate living with the condition.
In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.
1.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
2.
In inflammatory breast cancer, ER beta regulates estrogen signaling.
3.
Preferred and Actual Location of Death Often Don't Match for Young Cancer Patients
4.
Traces of bacteria inside brain tumors may affect tumor behavior
5.
Smart exercise planning could boost recovery for people with cancer
1.
Breaking Down the Benefits and Risks of Hematopoietic Stem Cell Transplantation
2.
Bridging Heart and Cancer Care: The Essential Framework of a Modern Cardio-Oncology Program
3.
Expanding Oncology Frontiers: Rare Cancers, Breakthroughs, and Precision Medicine Advances
4.
Everything You Need to Know About CA 19-9 and Cancer Diagnosis
5.
Hepatocellular Carcinoma: Progress in Detection, Pathogenesis, and Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
2.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
5.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge